Xilio Development Net Income
| XLO Stock | USD 0.55 0.01 1.85% |
As of the 10th of February, Xilio Development maintains the Standard Deviation of 2.94, market risk adjusted performance of (0.56), and Mean Deviation of 2.17. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xilio Development, as well as the relationship between them.
Xilio Development Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.9535 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -52.4 M | -55 M | |
| Net Loss | -79.4 M | -83.4 M | |
| Net Loss | -52.4 M | -55 M | |
| Net Loss | (1.25) | (1.31) |
Xilio | Net Income | Build AI portfolio with Xilio Stock |
Evaluating Xilio Development's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Xilio Development's fundamental strength.
Latest Xilio Development's Net Income Growth Pattern
Below is the plot of the Net Income of Xilio Development over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Xilio Development financial statement analysis. It represents the amount of money remaining after all of Xilio Development operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Xilio Development's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xilio Development's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (58.24 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Xilio Net Income Regression Statistics
| Arithmetic Mean | (37,177,920) | |
| Coefficient Of Variation | (69.54) | |
| Mean Deviation | 23,372,847 | |
| Median | (17,311,000) | |
| Standard Deviation | 25,855,136 | |
| Sample Variance | 668.5T | |
| Range | 70M | |
| R-Value | (0.77) | |
| Mean Square Error | 286.7T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (3,959,123) | |
| Total Sum of Squares | 10695.8T |
Xilio Net Income History
Other Fundumenentals of Xilio Development
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Xilio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Xilio Development is extremely important. It helps to project a fair market value of Xilio Stock properly, considering its historical fundamentals such as Net Income. Since Xilio Development's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xilio Development's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xilio Development's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Xilio diversify its offerings? Factors like these will boost the valuation of Xilio Development. Anticipated expansion of Xilio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xilio Development data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 7.425 | Return On Assets | Return On Equity |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Xilio Development's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Xilio Development 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xilio Development's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xilio Development.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Xilio Development on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Xilio Development or generate 0.0% return on investment in Xilio Development over 90 days. Xilio Development is related to or competes with PDS Biotechnology, Actinium Pharmaceuticals, Tempest Therapeutics, OnKure Therapeutics, Kezar Life, Skye Bioscience, and Tvardi Therapeutics. Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system ... More
Xilio Development Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xilio Development's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xilio Development upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 15.41 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 4.17 |
Xilio Development Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xilio Development's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xilio Development's standard deviation. In reality, there are many statistical measures that can use Xilio Development historical prices to predict the future Xilio Development's volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.57) |
Xilio Development February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 2.17 | |||
| Coefficient Of Variation | (561.82) | |||
| Standard Deviation | 2.94 | |||
| Variance | 8.64 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 15.41 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 4.17 | |||
| Skewness | (0.26) | |||
| Kurtosis | 1.28 |
Xilio Development Backtested Returns
Xilio Development shows Sharpe Ratio of -0.17, which attests that the company had a -0.17 % return per unit of risk over the last 3 months. Xilio Development exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Xilio Development's Mean Deviation of 2.17, market risk adjusted performance of (0.56), and Standard Deviation of 2.94 to validate the risk estimate we provide. The firm maintains a market beta of 0.94, which attests to possible diversification benefits within a given portfolio. Xilio Development returns are very sensitive to returns on the market. As the market goes up or down, Xilio Development is expected to follow. At this point, Xilio Development has a negative expected return of -0.51%. Please make sure to check out Xilio Development's total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Xilio Development performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.82 |
Very good predictability
Xilio Development has very good predictability. Overlapping area represents the amount of predictability between Xilio Development time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xilio Development price movement. The serial correlation of 0.82 indicates that around 82.0% of current Xilio Development price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.82 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Xilio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Xilio Development reported net income of (58.24 Million). This is 117.07% lower than that of the Biotechnology sector and 183.15% lower than that of the Health Care industry. The net income for all United States stocks is 110.2% higher than that of the company.
Xilio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xilio Development's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xilio Development could also be used in its relative valuation, which is a method of valuing Xilio Development by comparing valuation metrics of similar companies.Xilio Development is currently under evaluation in net income category among its peers.
Xilio Development Institutional Holders
Institutional Holdings refers to the ownership stake in Xilio Development that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Xilio Development's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Xilio Development's value.| Shares | Squarepoint Ops Llc | 2025-06-30 | 235.5 K | Balyasny Asset Management Llc | 2025-06-30 | 198.9 K | Renaissance Technologies Corp | 2025-06-30 | 164.2 K | Honkamp Krueger Financial Services Inc | 2025-06-30 | 142.3 K | Two Sigma Investments Llc | 2025-06-30 | 78 K | Northern Trust Corp | 2025-06-30 | 66.6 K | Bridgeway Capital Management, Llc | 2025-06-30 | 56.1 K | State Street Corp | 2025-06-30 | 43.4 K | Xtx Topco Ltd | 2025-06-30 | 34.7 K | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 4.6 M | Merck & Co Inc | 2025-06-30 | 1.5 M |
Xilio Fundamentals
| Return On Equity | -9.08 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.84) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | (59.53 M) | ||||
| Shares Outstanding | 67.54 M | ||||
| Shares Owned By Insiders | 35.34 % | ||||
| Shares Owned By Institutions | 23.49 % | ||||
| Number Of Shares Shorted | 2.09 M | ||||
| Price To Book | 5.87 X | ||||
| Price To Sales | 1.15 X | ||||
| Revenue | 6.34 M | ||||
| Gross Profit | 26.26 M | ||||
| EBITDA | (58 M) | ||||
| Net Income | (58.24 M) | ||||
| Cash And Equivalents | 159.41 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 8.14 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 9.17 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (18.38 M) | ||||
| Short Ratio | 5.70 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 64 | ||||
| Beta | -0.037 | ||||
| Market Capitalization | 36.53 M | ||||
| Total Asset | 71.08 M | ||||
| Retained Earnings | (383.75 M) | ||||
| Working Capital | 32.97 M | ||||
| Net Asset | 71.08 M |
About Xilio Development Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xilio Development's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xilio Development using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xilio Development based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Xilio Development
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xilio Development position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will appreciate offsetting losses from the drop in the long position's value.Moving together with Xilio Stock
Moving against Xilio Stock
| 0.76 | DSGN | Design Therapeutics | PairCorr |
| 0.74 | ENGN | enGene Holdings Common | PairCorr |
| 0.74 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.49 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.4 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Xilio Development could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xilio Development when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xilio Development - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xilio Development to buy it.
The correlation of Xilio Development is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xilio Development moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xilio Development moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xilio Development can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Biotechnology sector continue expanding? Could Xilio diversify its offerings? Factors like these will boost the valuation of Xilio Development. Anticipated expansion of Xilio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xilio Development data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 7.425 | Return On Assets | Return On Equity |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Xilio Development's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.